Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.
Merle HendersonSarah FidlerBeatriz MotheBeatriz GrinsztejnBridget HaireSimon CollinsJillian S Y LauMaureen LubaIan SanneRoger TatoudSteve DeeksSharon R LewinPublished in: Journal of the International AIDS Society (2022)
It can be assumed for the foreseeable future that SARS-CoV-2 will persist and continue to pose challenges to conducting clinical research in PLWH. Guidelines regarding how best to implement HIV treatment studies will evolve accordingly. The risks and benefits of performing an HIV clinical trial must be carefully evaluated in the local context on an ongoing basis. With this document, we hope to provide a broad guidance that should remain viable and relevant even as the nature of the pandemic continues to develop.
Keyphrases
- sars cov
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- coronavirus disease
- hepatitis c virus
- clinical trial
- hiv aids
- men who have sex with men
- respiratory syndrome coronavirus
- climate change
- clinical practice
- open label
- risk assessment
- current status
- study protocol
- smoking cessation